Walleye Capital’s Iovance Biotherapeutics IOVA Stock Holding History

Walleye Capital’s Portfolio IOVA Stock Details IOVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$903	Sell	217 -30,139	-99%	-$115K	﹤0.01%	4609
2026 Q1	$107K	Sell	30,356 -792,398	-96%	-$2.53M	﹤0.01%	3644
2025 Q4	$2.25M	Buy	822,754 +786,077	+2,143%	+$1.82M	0.01%	1773
2025 Q3	$79.6K	Buy	+36,677	New	+$86.6K	﹤0.01%	3819
2025 Q1	–	Sell	-35,235	Closed	-$261K	–	4652
2024 Q4	$261K	Buy	35,235 +21,570	+158%	+$200K	﹤0.01%	3545
2024 Q3	$128K	Sell	13,665 -3,665	-21%	-$34.7K	﹤0.01%	4280
2024 Q2	$139K	Buy	+17,330	New	+$186K	﹤0.01%	4543
2023 Q4	–	Sell	-19,819	Closed	-$104K	–	5209
2023 Q3	$90.2K	Buy	+19,819	New	+$129K	﹤0.01%	3983
2023 Q2	–	Sell	-26,299	Closed	-$188K	–	4577
2023 Q1	$161K	Buy	+26,299	New	+$181K	﹤0.01%	2633
2022 Q3	–	Sell	-14,467	Closed	-$160K	–	3377
2022 Q2	$160K	Sell	14,467 -177,126	-92%	-$2.32M	﹤0.01%	1601
2022 Q1	$3.19M	Sell	191,593 -44,553	-19%	-$689K	0.09%	249
2021 Q4	$4.51M	Buy	+236,146	New	+$5.2M	0.14%	158
2021 Q2	–	Sell	-13,922	Closed	-$441K	–	1426
2021 Q1	$441K	Buy	+13,922	New	+$577K	0.03%	623

Other funds holding IOVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

MFM

MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

Walleye Capital's IOVA Position: Q2 2026 in Review

Walleye Capital reduced its Iovance Biotherapeutics (IOVA) stake by 99% in Q2 2026, selling an estimated $115K and leaving 217 shares worth $903. The position accounts for ﹤0.01% of the portfolio, ranked #4609.

Walleye Capital first reported a position in IOVA in Q1 2021 and has held it in 13 quarters since. The position peaked at $4.51M in Q4 2021. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.

Walleye Capital held 217 shares of Iovance Biotherapeutics worth $903 as of Q2 2026.
Walleye Capital sold 30,139 Iovance Biotherapeutics shares in Q2 2026, an estimated $115K.
Iovance Biotherapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q2 2026, its #4609 holding.
Walleye Capital first reported a position in Iovance Biotherapeutics in Q1 2021 and has held it in 13 quarters since.
Walleye Capital's Iovance Biotherapeutics position peaked at $4.51M in Q4 2021.
292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.

Based on Walleye Capital's 13F filing for Q2 2026, filed 3 Aug 2026.